N4 PHARMA PLC — Environmental & Social Information 2019

Mar 28, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2523U

Evgen Pharma PLC

28 March 2019

For immediate release	28 March 2019

RNS REACH

Evgen Pharma plc

("Evgen" or "the Company")

Poster presentation from research collaboration with Imperial College London

Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, is pleased to announce that mechanistic data from the Company's research collaboration with Imperial College London (''Imperial'') are today being presented in a poster at the ABPP ("Activity-Based Protein Profiling") 2019 symposium in Belgium.  

Imperial's research work provides further insight into the potential mechanism of action of SFX-01 in metastatic breast cancer and identifies potential biomarkers for determining the efficacy of SFX-01 in this indication.

The poster can be viewed via this link http://www.evgen.com/pipeline/

Evgen's on-going collaboration with Imperial, funded principally by an Engineering and Physical Sciences Research Council Impact Acceleration Account grant, uses advanced chemical proteomics technology to identify targets for SFX-01 and also to identify potential biomarkers associated with efficacy in metastatic breast cancer and other diseases.

Earlier this week, Evgen announced its first Phase II clinical read-out of SFX-01 in metastatic breast cancer.  The headline data showed that SFX-01 had met its primary safety and efficacy endpoints in the STEM open label study, marking a highly significant step in the product's clinical development. 

Steve Franklin, CEO of Evgen Pharma, said:

''We are delighted that our collaboration with Professor Tate and Imperial College is already yielding results that will support and inform the development of SFX-01 in metastatic breast cancer and other diseases. Having announced positive Phase II clinical data in this indication earlier this week, it is particularly interesting to see results that may ultimately lead to one or more biomarkers that could potentially be used to help identify those patients that would be expected to have a better response to SFX-01.''

Enquiries:

Evgen Pharma plc Dr Stephen Franklin, CEO Richard Moulson, CFO www.evgen.com	c/o +44 (0) 20 7466 5000
finnCap Geoff Nash, Teddy Whiley (Corporate Finance) Alice Lane, Manasa Patil (ECM) www.finncap.com	+44 (0) 20 7220 0500
WG Partners LLP Nigel Barnes, Claes Spång	+44 (0) 20 3705 9330
Buchanan Mark Court, Sophie Wills, Tilly Abraham evgen@buchanan.uk.com	+44 (0) 20 7466 5000

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke.  The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

The Group commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 

For further information, please visit: www.evgen.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAJRMTTMBMTTFL